Robert Sambursky

Rapid Pathogen Screening, Inc. is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. The firm’s products include AdenoPlus, InflammaDry, FebriDx. The company was founded by Robert P. Sambursky and Robert W. VanDine in 2004 and is headquartered in Sarasota, FL.

RPS Diagnostics, Inc. develops diagnostic solutions and medical instruments. Its product FebriDx is in-office test that uses a finger stick blood sample to help differentiate viral from bacterial acute respiratory infection. The company was founded by Robert P. Sambursky in 2004 and is headquartered in Sarasota, FL.

Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA.

Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation.

Versa Holdings LLC provides investment services. The private company is based in Wilmington, DE.